[Treatment of acute cerebral infarction with PGI2--evaluating the clinical effect and observation of dynamic changes in plasma TXB2 and 6-keto PGF1 alpha levels].
18 patients with acute cerebral infarction were randomly subdivided into two groups: PGI2-treated group (11 cases) and low-molecular-weight Dextran-treated group (7 cases). Dosage of PGI2 was 2-5 ng/kg/min intravenous drip. Infusion was started within 72 hours after the onset of symptoms. The data showed that the plasma 6-keto-PGF1 alpha levels were increased, the plasma TXB2 levels, MAR as well as the scores of neurological deficit were decreased in the PGI2-treated group. The clinical improvement in PGI2-treated group is better than that in the dextran-treated group.
Zhao
J
J
Chongqing University of Medical Science.
D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002544:Cerebral Infarction / Q000097:blood / Q000188:drug therapy*; D011464:Epoprostenol / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D013929:Thromboxane B2 / Q000097:blood*
D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; D011464:Epoprostenol